We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Praised for striking ‘a great technical and commercial balance’, Addleshaw Goddard’s corporate and M&A team advises a diverse range of corporate clients, including blue-chip companies, on M&A, divestitures, joint ventures, corporate governance, and restructurings. With notable expertise in energy-related transactions, the team is also highly active in the retail, telecoms, healthcare, and private equity sectors. Co-head Roberto Pomares specialises in energy and PE deals, while Pablo Díaz brings a strong track record in M&A across the PE, industrial, and retail sectors, alongside his experience in corporate restructurings and governance matters. Key contributors also include Victoria Ruenes and Gonzalo Fernández, who provide support on high-end M&A transactions.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘What sets Addleshaw Goddard apart is the professionalism of its team and its in-depth knowledge of each type of consultation and collaboration undertaken.’
  • ‘In addition to their professionalism and knowledge, they provide an essential added value. Their closeness and empathy with the client are extraordinary. They not only advise but also share knowledge, building a relationship of mutual trust.’
Abbreviated data is displayed for this firm.

Key clients

  • EDP Renováveis
  • EDP Energías de Portugal
Abbreviated data is displayed for this firm.

Work highlights

  • Assisted Spanish satellite operator Hispasat with the creation of a consortium with Airbus Defence and Space, Eutelsat, SES and Thales Alenia Space, to take part in Project Iris 2, a European Commission programme for the design, financing, manufacture, launch, operation, maintenance and replacement of a constellation of telecoms satellites for government (civil and military) and commercial uses, owned by the European Union.
  • Advised Chinese multinational Haier Group Corporation on the $1.8bn cross-border acquisition of a 20% stake in Shanghai RAAS Blood Products from IBEX-35 pharmaceutical company Diagnostic Grifols S.A.
Abbreviated data is displayed for this firm.